```
 * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * *
FILE 'HOME' ENTERED AT 17:22:34 ON 04 AUG 2004
=> FILE BIOSIS, CABA, CAPLUS, EMBASE, JAPIO, LIFESCI, MEDLINE, SCISEARCH, USPATFULL
=> e brunham robert c/au
E1          1   BRUNHAM R R/AU
E2          6   BRUNHAM ROBERT/AU
E3        155 --> BRUNHAM ROBERT C/AU
E4          2   BRUNHAM ROBERT CONRAD/AU
E5          1   BRUNHAM ROBERT D/AU
E6          7   BRUNHAM S/AU
E7          3   BRUNHAM SANDRA/AU
E8          1   BRUNHAME R C/AU
E9          5   BRUNHANSEN H/AU
E10         1   BRUNHANSEN K/AU
E11         4   BRUNHARA F C/AU
E12         1   BRUNHARA FABIOLA C/AU

=> s e2-e4 and chlamyd?
L1        119 ("BRUNHAM ROBERT"/AU OR "BRUNHAM ROBERT C"/AU OR "BRUNHAM ROBERT
              CONRAD"/AU) AND CHLAMYD?

=> dup rem l1
PROCESSING COMPLETED FOR L1
L2         83 DUP REM L1 (36 DUPLICATES REMOVED)

=> s l2 and vector?
L3         18 L2 AND VECTOR?

=> d bib ab 1-
YOU HAVE REQUESTED DATA FROM 18 ANSWERS - CONTINUE? Y/(N):y

L3  ANSWER 1 OF 18  BIOSIS  COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN  2004:168815  BIOSIS
DN  PREV200400170674
TI  DNA immunization against  ***chlamydia***  infection.
AU    ***Brunham, Robert C.***  [Inventor, Reprint Author]
CS  Winnipeg, Canada
    ASSIGNEE: University of Manitoba, Winnipeg, Canada
PI  US 6696421 February 24, 2004
SO  Official Gazette of the United States Patent and Trademark Office Patents,
    (Feb 24 2004) Vol. 1279, No. 4. http://www.uspto.gov/web/menu/patdata.html
    . e-file.
    ISSN: 0098-1133 (ISSN print).
DT  Patent
LA  English
ED  Entered STN: 24 Mar 2004
    Last Updated on STN: 24 Mar 2004
AB  Nucleic acid, including DNA, immunization to generate a protective immune
    response in a host, including humans, to a major outer membrane protein of
    a strain of  ***Chlamydia***  , preferably contains a nucleotide sequence
    encoding a MOMP or a MOMP fragment that generates antibodies that
    specifically react with MOMP and a promoter sequence operatively coupled
    to the first nucleotide sequence for expression of the MOMP in the host.
    The non-replicating  ***vector***  may be formulated with a
    pharmaceutically acceptable carrier for in vivo administration to the
    host.

L3  ANSWER 2 OF 18  BIOSIS  COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN  2002:183809  BIOSIS
DN  PREV200200183809
TI  DNA immunization against chlaymdia infection.
AU    ***Brunham, Robert C.***  [Inventor, Reprint author]
CS  Winnipeg, Canada
    ASSIGNEE: University of Manitoba, Winnipeg, Canada
PI  US 6344202 February 05, 2002
SO  Official Gazette of the United States Patent and Trademark Office Patents,
    (Feb. 5, 2002) Vol. 1255, No. 1. http://www.uspto.gov/web/menu/patdata.htm
```

l. e-file.
CODEN: OGUPE7. ISSN: 0098-1133.
DT Patent
LA English
ED Entered STN: 6 Mar 2002
Last Updated on STN: 6 Mar 2002
AB Nucleic acid, including DNA, for immunization to generate a protective immune response in a host, including humans, to a major outer membrane protein of a strain of ***Chlamydia*** , preferably contains a nucleotide sequence encoding a MOMP or a MOMP fragment that generates antibodies that specifically react with MOMP and a promoter sequence operatively coupled to the first nucleotide sequence for expression of the MOMP in the host. The non-replicating ***vector*** may be formulated with a pharmaceutically-acceptable carrier for in vivo administration to the host.

L3 ANSWER 3 OF 18 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 2001:521512 BIOSIS
DN PREV200100521512
TI DNA immunization against chlaymdia infection.
AU ***Brunham, Robert C.*** [Inventor, Reprint author]
CS Winnipeg, Canada
ASSIGNEE: University of Manitoba, Winnipeg, Canada
PI US 6235290 May 22, 2001
SO Official Gazette of the United States Patent and Trademark Office Patents, (May 22, 2001) Vol. 1246, No. 4. e-file.
CODEN: OGUPE7. ISSN: 0098-1133.
DT Patent
LA English
ED Entered STN: 7 Nov 2001
Last Updated on STN: 23 Feb 2002
AB Nucleic acid, including DNA, immunization to generate a protective immune response in a host, including humans, to a major outer membrane protein of a strain of ***Chlamydia*** , preferably contains a nucleotide sequence encoding a MOMP or a MOMP fragment that generates antibodies that specifically react with MOMP and a promoter sequence operatively coupled to the first nucleotide sequence for expression of the MOMP in the host. The non-replicating ***vector*** may be formulated with a pharmaceutically-acceptable carrier for in vivo administration to the host.

L3 ANSWER 4 OF 18 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 1996:324302 BIOSIS
DN PREV199699046658
TI Risk factors for ***Chlamydia*** trachomatis pelvic inflammatory disease among sex workers in Nairobi, Kenya.
AU Kimani, Joshua; MacLean, Ian W.; Bwayo, Job J.; MacDonald, Kelly; Oyugi, Julius; Maitha, Gregory M.; Peeling, Rosanna W.; Cheang, Mary; Nagelkerke, Nicolaas J. D.; Plummer, Francis A.; ***Brunham, Robert C.*** [Reprint author]
CS Dep. Med. Microbiol., Univ. Manitoba, Room 543, 730 William Ave., Winnipeg, Manitoba R3E 0W3, Canada
SO Journal of Infectious Diseases, (1996) Vol. 173, No. 6, pp. 1437-1444.
CODEN: JIDIAQ. ISSN: 0022-1899.
DT Article
LA English
ED Entered STN: 11 Jul 1996
Last Updated on STN: 11 Jul 1996
AB Among 302 female sex workers in Nairobi, Kenya, who were followed for 17.6 + 11.1 months, 146 had one or more infections with ***Chlamydia*** trachomatis; 102 had uncomplicated cervical infection only, 23 had C. trachomatis pelvic inflammatory disease (PID), and 21 had combined C. trachomatis and Neisseria gonorrhoeae PID. As determined by multivariate logistic regression analysis, risk factors for C. trachomatis PID included repeated C. trachomatis infection (odds ratio (OR), 1.8; 95% confidence interval (CI), 1.3-2.4; P = .0004), antibody to C. trachomatis heat-shock protein 60 (OR, 3.9; CI, 1.04-14.5; P = .04), oral contraceptive use (OR,

0.28; 95% CI, 0.08-0.99; P = .048), and number of episodes of nongonococcal nonchlamydial PID (OR, 1.7; 95% CI, 1.1-2.7; P = .02). Among human immunodeficiency virus (HIV)-seropositive women, a CD4 lymphocyte count of lt 400/mm-3 was an additional independent risk factor for C. trachomatis PID (OR, 21.7; 95% CI, 1.2-383; P = .036); among HLA-typed women, HLA-A31 was independently associated with C. trachomatis PID (OR, 5.6; 95% CI, 1.1-29.4; P = .043). The results suggest an immune-mediated pathogenesis for C. trachomatis PID.

L3 ANSWER 5 OF 18 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 1996:275467 BIOSIS
DN PREV199698831596
TI The epidemiology of ***Chlamydia*** trachomatis within a sexually transmitted diseases core group.
AU ***Brunham, Robert C.*** [Reprint author]; Kimani, Joshua; Bwayo, Job; Maitha, Gregory; MacLean, Ian; Yang, Chunlin; Shen, Caixia; Roman, Susan; Nagelkerke, Nico J. D.; Cheang, Mary; Plummer, Francis A.
CS Dep. Med. Microbiol., Univ. Manitoba, Room 543, 730 William Ave., Winnipeg, MB R3E 0W3, Canada
SO Journal of Infectious Diseases, (1996) Vol. 173, No. 4, pp. 950-956. CODEN: JIDIAQ. ISSN: 0022-1899.
DT Article
LA English
ED Entered STN: 10 Jun 1996
Last Updated on STN: 10 Jun 1996
AB Female sex workers in Nairobi were prospectively evaluated for risk factors of incident ***Chlamydia*** trachomatis infection. Independent risk factors included cervical ectopy (P = .007), gonococcal infection (P = .002), human immunodeficiency virus (HIV) seropositivity (P = .003), HIV seroconversion (P = .001), and duration of prostitution (P = .002). Eighteen different C. trachomatis outer membrane protein (omp1) genotypes were identified, with the allelic composition of the C. trachomatis population changing significantly over time (P = .005). Seventeen of 19 reinfections gtoreq 6 months apart were with different C. trachomatis omp1 genotypes. Women with HIV infection had an increased proportion of visits with C. trachomatis infection (P = .001) and an increased risk of reinfection (P = .008). Overall, the data demonstrate significant fluctuations in the genotype composition of the C. trachomatis population and a reduced rate of same-genotype reinfection consistent with the occurrence of strain-specific immunity.

L3 ANSWER 6 OF 18 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 1995:284692 BIOSIS
DN PREV199598298992
TI STD transmission dynamics and control.
AU ***Brunham, Robert C.***
CS Univ. Manitoba, Manitoba, Canada
SO Journal of Cellular Biochemistry Supplement, (1995) Vol. 0, No. 21B, pp. 250.
Meeting Info.: Keystone Symposium on Sexually Transmitted Diseases in the HIV Era. Keystone, Colorado, USA. April 17-23, 1995.
ISSN: 0733-1959.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 5 Jul 1995
Last Updated on STN: 5 Jul 1995

L3 ANSWER 7 OF 18 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 1995:41977 BIOSIS
DN PREV199598056277
TI Epidemiology of Infection Due to ***Chlamydia*** trachomatis in Manitoba, Canada.
AU Orr, Pamela [Reprint author]; Sherman, Elizabeth; Blanchard, James; Fast, Margaret; Hammond, Gregory; ***Brunham, Robert***
CS Dep. Med. Microbiol., Univ. Manitoba, Room 503, 730 William Ave., Winnipeg, Manitoba R3E 0W3, Canada

SO Clinical Infectious Diseases, (1994) Vol. 19, No. 5, pp. 876-883.
CODEN: CIDIEL. ISSN: 1058-4838.
DT Article
LA English
ED Entered STN: 25 Jan 1995
Last Updated on STN: 25 Jan 1995
AB In a study of the epidemiology of ***Chlamydia*** trachomatis infection in Manitoba during 1981-1990, we retrospectively reviewed laboratory and clinical case notification records as well as hospital and health insurance data concerning pelvic inflammatory disease and ectopic pregnancy. After implementation of a control program in 1987, the annual incidence of ***chlamydial*** infection was highest among females aged 15-24 years (3,418 cases per 100,000 residents). Recurrent infection, which occurred in 13.4% of patients, was more common in women (P lt .001), patients aged 15-24 years (P lt .001), registered North American Indians (P lt .001), and persons with concomitant gonorrhea (P lt .001). Risk factors for dual (***chlamydial*** and gonococcal) infection included male sex (P lt .001) and young age (P lt .001). Although the incidence of hospitalizations and outpatient visits for pelvic inflammatory disease decreased (P lt .001) from 1981 to 1990, the annual incidence of ectopic pregnancy increased from 10 to 16 cases per 1,000 reported pregnancies (P lt .001). Control activities focusing on the primary prevention of C. trachomatis infection are presented. Strategies for improving secondary prevention (through case detection and treatment of lower genital infection) include the targeting of individuals with recurrent and multiple sexually transmitted diseases.

L3 ANSWER 8 OF 18 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 1994:499630 BIOSIS
DN PREV199497512630
TI Conformational mimicry of a ***chlamydial*** neutralization epitope on filamentous phage.
AU Zhong, Guangming [Reprint author]; Smith, George P.; Berry, Jody; ***Brunham, Robert C.***
CS Lab. Immunol., NIAID, NIH, Building 10, Room 11N311, Bethesda, MD 20892, USA
SO Journal of Biological Chemistry, (1994) Vol. 269, No. 39, pp. 24183-24188.
CODEN: JBCHA3. ISSN: 0021-9258.
DT Article
LA English
ED Entered STN: 28 Nov 1994
Last Updated on STN: 28 Nov 1994
AB Conformational constraints were imposed on a peptide epitope from ***Chlamydia*** trachomatis to improve its ability to elicit antibodies that cross-react with native antigen. Appropriate constraints were discovered by a strategy that required no prior knowledge of the epitope's native conformation. First, we constructed a library of 3.2 times 10-5 peptides in which the epitope's contact residues were subject to random conformational constraints, each constrained peptide being fused genetically to the surface of a filamentous phage ***vector*** . Next, we selected phage displaying the most native-like peptides in the library by affinity purification with antibodies that bind the epitope only in its native conformation. Finally, we immunized mice with the selected phage and titered the resulting antisera against both whole cells and unconstrained peptide. The ratio of anti-cell titer to anti-peptide titer, which reflects the channeling of the antibody response to the native epitope, was up to five times higher for affinity-selected phage than for unselected peptide phage. In this case, therefore, "antigenic fitness", the ability of a peptide to bind antibodies specific for native epitope, correlated with "immunogenic fitness", its ability to elicit antibodies that are effective against the native antigen on an invading pathogen. If the correlation is general, surveying thousands or millions of peptides for antigenic fitness with phage display technology may be a simple but effective pre-screen for immunogenic fitness, which is costly to assess directly.

L3 ANSWER 9 OF 18 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN

AN 1993:348344 BIOSIS
DN PREV199396045344
TI ***Chlamydia*** trachomatis, infertility, and population growth in sub-Saharan Africa.
AU ***Brunham, Robert C.*** [Reprint author]; Cheang, Mary; McMaster, Jeff; Garnett, Geoff; Anderson, Roy
CS Dep. Med. Microbiol., Univ. Manitoba, Room 543, 730 William Ave., Winnipeg, MB, Can. R3E 0W3, canada
SO Sexually Transmitted Diseases, (1993) Vol. 20, No. 3, pp. 168-173. ISSN: 0148-5717.
DT Article
LA English
ED Entered STN: 26 Jul 1993
Last Updated on STN: 26 Jul 1993
AB In sub-Saharan Africa, Neisseria gonorrhoeae and ***Chlamydia*** trachomatis are common infections. These pathogens are also the major causes of post-salpingitis tubal infertility, and infertility is a frequent problem in this region. A mathematical model, recently devised to estimate the effect of gonococcal infection on population growth, was used to estimate the potential effect of ***chlamydial*** infection on population growth. The model predictions for ***chlamydial*** infection were compared with those previously reported for gonococcal infection. The model predicts that both infections may be exerting severe effects on population growth at realistic prevalence rates of infection. The model also predicts that N. gonorrhoeae produces a steeper reduction in population growth than does C. trachomatis because its transmission dynamics result in a higher force of infection (incidence rate) at any given prevalance of infection. Large scale changes in the epidemiology of these infections can be expected to occur in sub-Saharan Africa because of improved sexually transmitted disease (STD) diagnosis and treatment services as a component of AIDS prevention. Changes in the epidemiology of gonococcal and ***chlamydial*** infection are predicted to result in accelerated population growth unless STD control programs are linked to effective contraception programs.

L3 ANSWER 10 OF 18 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:229055 CAPLUS
DN 134:251203
TI Cloning and expression of serine-threonine kinase (STK) gene of ***Chlamydia*** for immunization against infections
IN ***Brunham, Robert C.***
PA University of Manitoba, Can.
SO PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001021811	A1	20010329	WO 2000-CA1097	20000921
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6632663	B1	20031014	US 1999-401780	19990922
EP 1222283	A1	20020717	EP 2000-962134	20000921
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
NZ 518283	A	20031031	NZ 2002-518283	20020410
PRAI US 1999-401780	A	19990922		
WO 2000-CA1097	W	20000921		

AB Nucleic acid, including DNA, immunization is used to generate a protective

immune response in a host, including humans, to a serine-threonine kinase (STK) of a strain of ***Chlamydia*** . A non-replicating ***vector*** , including a plasmid ***vector*** , contains a nucleotide sequence encoding an STK or a fragment of the STK that generates antibodies that specifically react with STK and a promoter sequence operatively coupled to the first nucleotide sequence for expression of the STK in the host. The non-replicating ***vector*** may be formulated with a pharmaceutically-acceptable carrier for in vivo administration to the host.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1998:71227 CAPLUS
DN 128:137176
TI Cloning and expression of major outer membrane protein gene of ***Chlamydia*** for immunization against infections
IN ***Brunham, Robert C.***
PA University of Manitoba, Can.; Brunham, Robert C.
SO PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 4

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9802546	A2	19980122	WO 1997-CA500	19970711
WO 9802546	A3	19980226		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2259595	AA	19980122	CA 1997-2259595	19970711
AU 9734314	A1	19980209	AU 1997-34314	19970711
AU 723235	B2	20000824		
EP 915978	A2	19990519	EP 1997-930277	19970711
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2000503325	T2	20000321	JP 1998-505478	19970711
NZ 334114	A	20000623	NZ 1997-334114	19970711
BR 9712971	A	20020507	BR 1997-12971	19970711
US 2002110542	A1	20020815	US 1999-214606	19990812
US 6696421	B2	20040224		
PRAI US 1996-21607P	P	19960712		
WO 1997-CA500	W	19970711		

AB Nucleic acids, including DNA, immunization to generate a protective immune response in a host, including humans, to a major outer membrane protein of a strain of ***Chlamydia*** trachomatis, preferably contains a nucleotide sequence encoding a major outer membrane protein (MOMP) or a N-terminal MOMP fragment that generates antibodies that specifically react with MOMP and a promoter sequence operatively coupled to the first nucleotide sequence for expression of the MOMP in the host. Plasmid ***vectors*** such as pcDNA3 are prepd. which also contain gene regulatory elements such as the human cytomegalovirus promoter. The non-replicating ***vector*** may be formulated with a pharmaceutically-acceptable carrier for in vivo administration (intranasal) to the human host.

L3 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1990:152644 CAPLUS
DN 112:152644
TI The 75-kilodalton protein of ***Chlamydia*** trachomatis: a member of the heat shock protein 70 family?

AU Danilition, Sandra L.; Maclean, Ian W.; Peeling, Rosanna; Winston, Scott; ***Brunham, Robert C.***
CS Dep. Med. Microbiol., Univ. Manitoba, Winnipeg, MB, R3E 0W3, Can.
SO Infection and Immunity (1990), 58(1), 189-96
CODEN: INFIBR; ISSN: 0019-9567
DT Journal
LA English
AB The gene encoding a 75 kDa protein of C. trachomatis was cloned, expressed, and sequenced. Genomic libraries from C. trachomatis serovar D DNA were constructed in ***vectors*** pUC18 and .lambda.gt11 and were screened with a panel of monoclonal antibodies against C. trachomatis antigens. The only recombinants identified were those that reacted with antibody UM-13, which has specificity for a genus-specific epitope on the 75 kDa protein. The gene was localized to a 2.9 kb DNA fragment and sequenced. The gene consists of a long open reading frame of 1956 nucleotides, which translates into 652 amino acids totalling 70,558 Da in mass. Putative promoter elements and a ribosome binding site were identified within 5'-flanking sequences, and a typical rho-independent terminator was identified within 3'-flanking sequences. Screening of the GenBank nucleic acid sequence data bank revealed extensive similarity between the ***chlamydial*** 75 kDa gene and the heat shock protein 70 (hsp70) family of proteins. In particular, 71 and 69% amino acid sequence similarities were identified with hsp70 of Escherichia coli and Bacillus megaterium, resp. Polyclonal antibodies were produced to the recombinant antigen in rabbits and detected epitopes on elementary bodies in enzyme-linked immunosorbent and indirect microimmunofluorescence assays. Antibodies reacted with an antigen of identical mol. mass in L2 and C serovars in an immunoblot assay and neutralized these serovars in cell culture. The 75-kDa protein appears to be a ***chlamydial*** homolog of hsp70, is immunoaccessible on native elementary bodies, and is a target for neutralization.

L3 ANSWER 13 OF 18 USPATFULL on STN
AN 2004:171470 USPATFULL
TI Two-step immunization procedure against ***chlamydia*** infection
IN ***Brunham, Robert C.*** , Vancouver, CANADA
Murdin, Andrew D., Newmarket, CANADA
PI US 2004131630 A1 20040708
AI US 2003-699683 A1 20031104 (10)
RLI Division of Ser. No. US 1999-453289, filed on 3 Dec 1999, GRANTED, Pat. No. US 6676949
PRAI US 1998-110855P 19981204 (60)
DT Utility
FS APPLICATION
LREP Michael I. Stewart, Sim & McBurney, 6th Floor, 330 University Avenue, Toronto, ON, M5G 1R7
CLMN Number of Claims: 40
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 695
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A host is immunized against infection by a strain of ***Chlamydia*** by initial administration of an attenuated bacteria harbouring a nucleic acid encoding a ***Chlamydia*** protein followed by administration of a ***Chlamydia*** protein in ISCOMs. This procedure enables a high level of protection to be achieved.

L3 ANSWER 14 OF 18 USPATFULL on STN
AN 2004:164896 USPATFULL
TI Two-step immunization procedure against ***chlamydia*** infection
IN ***Brunham, Robert C.*** , Vancouver, CANADA
Murdin, Andrew D., Newmarket, CANADA
PI US 2004126382 A1 20040701
AI US 2003-699882 A1 20031104 (10)
RLI Division of Ser. No. US 1999-453289, filed on 3 Dec 1999, GRANTED, Pat. No. US 6676949
PRAI US 1998-110855P 19981204 (60)

DT Utility
FS APPLICATION
LREP Michael I. Stewart, Sim & McBurney, 6th Floor, 330 University Avenue, Toronto, ON, M5G 1R7
CLMN Number of Claims: 40
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 696
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A host is immunized against infection by a strain of ***Chlamydia*** by initial administration of an attenuated bacteria harbouring a nucleic acid encoding a ***Chlamydia*** protein followed by administration of a ***Chlamydia*** protein in ISCOMs. This procedure enables a high level of protection to be achieved.

L3 ANSWER 15 OF 18 USPATFULL on STN
AN 2003:273363 USPATFULL
TI DNA immunization against ***chlamydia*** infection
IN ***Brunham, Robert C.*** , Winnipeg, CANADA
PA Aventis Pasteur Limited, Toronto, CANADA (non-U.S. corporation)
PI US 6632663 B1 20031014
AI US 1999-401780 19990922 (9)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Shukla, Ram R.
LREP Sim & McBurney
CLMN Number of Claims: 1
ECL Exemplary Claim: 1
DRWN 5 Drawing Figure(s); 4 Drawing Page(s)
LN.CNT 620
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Nucleic acid, including DNA, immunization is used to generate a protective immune response in a host, including humans, to a serine-threonine kinase (STK) of a strain of ***Chlamydia*** . A non-replicating ***vector*** , including a plasmid ***vector*** , contains a nucleotide sequence encoding a STK or a fragment of the STK that generates antibodies that specifically react with STK and a promoter sequence operatively coupled co the first nucleotide sequence for expression of the STK in the host. The non-replicating ***vector*** may be formulated with a pharmaceutically-acceptable carrier for in vivo administration to the host.

L3 ANSWER 16 OF 18 USPATFULL on STN
AN 2002:300839 USPATFULL
TI TWO-STEP IMMUNIZATION PROCEDURE AGAINST ***CHLAMYDIA*** INFECTION
IN ***Brunham, Robert C.*** , 2077 655 West 12th Avenue, Vancouver, BC, CANADA V5Z4R4
Murdin, Andrew D., 146 Rhodes Circle, Newmarket, ON, CANADA L3X1V2
PI US 2002168382 A1 20021114
US 6676949 B2 20040113
AI US 1999-453289 A1 19991203 (9)
PRAI US 1998-110855P 19981204 (60)
DT Utility
FS APPLICATION
LREP SIM & MCBURNEY, 330 UNIVERSITY AVENUE, 6TH FLOOR, TORONTO, M5G1R7
CLMN Number of Claims: 40
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 689
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A host is immunized against infection by a strain of ***Chlamydia*** by initial administration of an attenuated bacteria harbouring a nucleic acid encoding a ***Chlamydia*** protein followed by administration of a ***Chlamydia*** protein in ISCOMs. This procedure enables a high level of protection to be achieved.

L3 ANSWER 17 OF 18 USPATFULL on STN

AN 2002:258434 USPATFULL
TI DNA immunization against Chlaymdia infection
IN ***Brunham, Robert C.*** , Winnipeg, CA, UNITED STATES
PI US 2002142001 A1 20021003
AI US 2002-36507 A1 20020107 (10)
RLI Division of Ser. No. US 1998-55765, filed on 7 Apr 1998, GRANTED, Pat. No. US 6344202 Continuation-in-part of Ser. No. US 1997-893381, filed on 11 Jul 1997, GRANTED, Pat. No. US 6235290
PRAI US 1996-21607P 19960712 (60)
DT Utility
FS APPLICATION
LREP SIM & MCBURNEY, 330 UNIVERSITY AVENUE, 6TH FLOOR, TORONTO, ON, M5G 1R7
CLMN Number of Claims: 49
ECL Exemplary Claim: 1
DRWN 26 Drawing Page(s)
LN.CNT 1208
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Nucleic acid, including DNA, for immunization to generate a protective immune response in a host, including humans, to a major outer membrane protein of a strain of ***Chlamydia*** , preferably contains a nucleotide sequence encoding a MOMP or a MOMP fragment that generates antibodies that specifically react with MOMP and a promoter sequence operatively coupled to the first nucleotide sequence for expression of the MOMP in the host. The non-replicating ***vector*** may be formulated with a pharmaceutically-acceptable carrier for in vivo administration to the host.

L3 ANSWER 18 OF 18 USPATFULL on STN
AN 2002:205855 USPATFULL
TI DNA IMMUNIZATION AGAINST ***CHLAMYDIA*** INFECTION
IN ***BRUNHAM, ROBERT C.*** , WINNIPEG, CANADA
PI US 2002110542 A1 20020815
US 6696421 B2 20040224
AI US 1999-214606 A1 19990812 (9)
WO 1997-CA500 19970711
DT Utility
FS APPLICATION
LREP SIM & MCBURNEY, 330 UNIVERSITY AVENUE, 6TH FLOOR, TORONTO, M5G1R7
CLMN Number of Claims: 33
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 878
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Nucleic acid, including DNA, immunization to generate a protective immune response in a host, including humans, to a major outer membrane protein of a strain of ***Chlamydia*** , preferably contains a nucleotide sequence encoding a MOMP or a MOMP fragment that generates antibodies that specifically react with MOMP and a promoter sequence operatively coupled to the first nucleotide sequence for expression of the MOMP in the host. The nonreplicating ***vector*** may be formulated with a pharmaceutically acceptable carrier for in vivo administration to the host.

=> s chlamyd? and vector? and nonreplicating
L4 45 CHLAMYD? AND VECTOR? AND NONREPLICATING

=> dup rem l4
PROCESSING COMPLETED FOR L4
L5 45 DUP REM L4 (0 DUPLICATES REMOVED)

=> d bib ab 1-
YOU HAVE REQUESTED DATA FROM 45 ANSWERS - CONTINUE? Y/(N):y

L5 ANSWER 1 OF 45 USPATFULL on STN
AN 2004:152148 USPATFULL
TI Retroductal salivary gland genetic vaccination

IN Tucker, Sean, San Francisco, CA, UNITED STATES
Bennett, Michael, El Sobrante, CA, UNITED STATES
Chen, Yen-Ju, Alameda, CA, UNITED STATES
Olson, David, Alameda, CA, UNITED STATES
PA Genteric, Inc., Alameda, CA (U.S. corporation)
PI US 2004116370 A1 20040617
AI US 2003-649106 A1 20030826 (10)
PRAI US 2002-407375P 20020830 (60)
US 2003-453999P 20030311 (60)
DT Utility
FS APPLICATION
LREP TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834
CLMN Number of Claims: 51
ECL Exemplary Claim: 1
DRWN 21 Drawing Page(s)
LN.CNT 2307
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides compositions and methods for eliciting an immune response and compositions and methods for transfecting antigen presenting cells.

L5 ANSWER 2 OF 45 USPATFULL on STN
AN 2004:120585 USPATFULL
TI Recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses
IN Schlom, Jeffrey, Potomac, MD, UNITED STATES
Greiner, John W., Ijamsville, MD, UNITED STATES
Kass, Erik, Chevy Chase, MD, UNITED STATES
Panicali, Dennis, Acton, MA, UNITED STATES
PI US 2004091995 A1 20040513
AI US 2003-297168 A1 20030716 (10)
WO 2001-US19201 20010615
DT Utility
FS APPLICATION
LREP HELLER EHRMAN WHITE & MCAULIFFE LLP, 1666 K STREET,NW, SUITE 300, WASHINGTON, DC, 20006
CLMN Number of Claims: 114
ECL Exemplary Claim: 1
DRWN 24 Drawing Page(s)
LN.CNT 2984
AB Replication-defective recombinant poxvirus encoding granulocyte-macrophage colony-stimulating factor (GM-CSF) are disclosed for use in enriching an immunization site with antigen-presenting cells (APC), for enhancing an immunological response to antigen or immunological epitopes by functioning as a biological adjuvant, for prevention or treatment of neutropenia, and for the treatment of myeloidysplastic syndromes. Compositions comprising a replication-defective recombinant virus encoding GM-CSF alone or in combination with a recombinant virus encoding an antigen and optionally encoding an immunostimulatory molecule are disclosed for enhancing antigen-specific immunological responses, in particular enhancing tumor antigen responses for anti-tumor therapy. Methods for enriching an immunization site with APC and for enhancing immunological responses to an antigen or immunological epitope using replication-defective recombinant poxvirus encoding GM-CSF are disclosed. The superiority of the use of a replication-defective recombinant avian poxvirus encoding GM-CSF over the use of recombinant GM-CSF is described.

L5 ANSWER 3 OF 45 USPATFULL on STN
AN 2004:38740 USPATFULL
TI Packaging of positive-strand rna virus replicon particles
IN Kovacs, Gerald R., Rockville, MD, UNITED STATES
Vasilakis, Nikos, Galveston, TX, UNITED STATES
Kowalski, Jacek, Mahwah, NJ, UNITED STATES
Gangolli, Seema, Park Ridge, NJ, UNITED STATES
Zamb, Timothy, Nyack, NY, UNITED STATES

PI US 2004029279 A1 20040212
AI US 2003-363082 A1 20030827 (10)
WO 2001-US41888 20010828
DT Utility
FS APPLICATION
LREP WYETH, PATENT LAW GROUP, FIVE GIRALDA FARMS, MADISON, NJ, 07940
CLMN Number of Claims: 53
ECL Exemplary Claim: 1
DRWN 24 Drawing Page(s)
LN.CNT 2329
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention generally relates to recombinant polynucleotides, positive-strand RNA virus (psRNAV) recombinant expression ***vectors*** , and packaging systems. The packaging systems are based on the expression of helper functions by coinfecting re-combinant poxvirus ***vectors*** comprising recombinant polynucleotides. Methods for obtaining psRNAV replicon particles using these packaging systems are disclosed. Immunogenic compositions and pharmaceutical formulations are provided that comprise replicon particles of the invention. Methods for generating an immune response or producing a pharmaceutical effect are also provided.

L5 ANSWER 4 OF 45 USPATFULL on STN
AN 2004:7465 USPATFULL
TI Poroplasts
IN Surber, Mark W., Coronado, CA, UNITED STATES
Giacalone, Matthew, San Diego, CA, UNITED STATES
PI US 2004005700 A1 20040108
AI US 2002-157339 A1 20020528 (10)
DT Utility
FS APPLICATION
LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR, IRVINE, CA, 92614
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 18539
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnostic and therapeutic uses, as well as research tools and agents for drug discovery.

L5 ANSWER 5 OF 45 USPATFULL on STN
AN 2004:72626 USPATFULL
TI Methods and treatment of multiple sclerosis
IN Stratton, Charles W., Nashville, TN, United States
Mitchell, William M., Nashville, TN, United States
Sriram, Subramaniam, Nashville, TN, United States
PA Vanderbilt University, Nashville, TN, United States (U.S. corporation)
PI US 6710033 B1 20040323
AI US 2000-528348 20000317 (9)
RLI Continuation-in-part of Ser. No. US 1998-73661, filed on 6 May 1998
Continuation-in-part of Ser. No. US 1998-25174, filed on 18 Feb 1998
Continuation-in-part of Ser. No. US 1997-911593, filed on 14 Aug 1997
PRAI US 1996-23921P 19960814 (60)
US 1999-125598P 19990319 (60)
US 2000-176662P 20000118 (60)
US 2000-176940P 20000118 (60)
US 2000-176784P 20000118 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Weddington, Kevin E.
LREP Clark & Elbing LLP
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN 44 Drawing Figure(s); 16 Drawing Page(s)

LN.CNT 2356
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention features methods and reagents for the diagnosis, monitoring, and treatment of multiple sclerosis. The invention is based in part on the discovery that ***Chlamydia*** is present in patients with multiple sclerosis, and that anti- ***chlamydial*** agents improve or sustain neurological function in these patients.

L5 ANSWER 6 OF 45 USPATFULL on STN
AN 2003:330124 USPATFULL
TI Minicell-based screening for compounds and proteins that modulate the activity of signalling proteins
IN Surber, Mark W., Coronado, CA, UNITED STATES
Berkley, Neil, San Diego, CA, UNITED STATES
PI US 2003232335 A1 20031218
AI US 2002-157317 A1 20020528 (10)
PRAI US 2002-359843P 20020225 (60)
DT Utility
FS APPLICATION
LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR, IRVINE, CA, 92614
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 18564
AB The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.

L5 ANSWER 7 OF 45 USPATFULL on STN
AN 2003:318700 USPATFULL
TI Antibodies to native conformations of membrane proteins
IN Sabbadini, Roger A., Lakeside, CA, UNITED STATES
Berkley, Neil, San Diego, CA, UNITED STATES
Surber, Mark W., Coronado, CA, UNITED STATES
PI US 2003224444 A1 20031204
AI US 2002-157491 A1 20020528 (10)
PRAI US 2002-359843P 20020225 (60)
DT Utility
FS APPLICATION
LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR, IRVINE, CA, 92614
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 18559
AB The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.

L5 ANSWER 8 OF 45 USPATFULL on STN
AN 2003:318625 USPATFULL
TI Reverse screening and target identification with minicells
IN Surber, Mark W., Coronado, CA, UNITED STATES
Berkley, Neil, San Diego, CA, UNITED STATES
Gerhart, William, La Mesa, CA, UNITED STATES
PI US 2003224369 A1 20031204
AI US 2002-157171 A1 20020528 (10)
PRAI US 2002-359843P 20020225 (60)
DT Utility
FS APPLICATION
LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR, IRVINE, CA, 92614
CLMN Number of Claims: 20
ECL Exemplary Claim: 1

DRWN 2 Drawing Page(s)
LN.CNT 18610
AB The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.

L5 ANSWER 9 OF 45 USPATFULL on STN
AN 2003:318218 USPATFULL
TI Methods and reagents for the treatment of multiple sclerosis
IN Stratton, Charles W., Nashville, TN, UNITED STATES
Mitchell, William M., Nashville, TN, UNITED STATES
Sriram, Subramaniam, Nashville, TN, UNITED STATES
PI US 2003223959 A1 20031204
AI US 2003-419034 A1 20030417 (10)
RLI Continuation of Ser. No. US 2000-528348, filed on 17 Mar 2000, PENDING Continuation-in-part of Ser. No. US 1998-73661, filed on 6 May 1998, GRANTED, Pat. No. US 6579854 Continuation-in-part of Ser. No. US 1998-25174, filed on 18 Feb 1998, GRANTED, Pat. No. US 6562582 Continuation-in-part of Ser. No. US 1997-911593, filed on 14 Aug 1997, ABANDONED
PRAI US 1999-125598P 19990319 (60)
US 2000-176662P 20000118 (60)
US 2000-176940P 20000118 (60)
US 2000-176784P 20000118 (60)
DT Utility
FS APPLICATION
LREP CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 16 Drawing Page(s)
LN.CNT 2445
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention features methods and reagents for the diagnosis, monitoring, and treatment of multiple sclerosis. The invention is based in part on the discovery that ***Chlamydia*** is present in patients with multiple sclerosis, and that anti- ***chlamydial*** agents improve or sustain neurological function in these patients.

L5 ANSWER 10 OF 45 USPATFULL on STN
AN 2003:312291 USPATFULL
TI Minicell-based bioremediation
IN Segall, Anca M., San Diego, CA, UNITED STATES
Klepper, Robert, San Diego, CA, UNITED STATES
PI US 2003219888 A1 20031127
AI US 2002-157418 A1 20020528 (10)
RLI Division of Ser. No. US 2002-154951, filed on 24 May 2002, PENDING
PRAI US 2002-359843P 20020225 (60)
US 2001-293566P 20010524 (60)
DT Utility
FS APPLICATION
LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR, IRVINE, CA, 92614
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 18632
AB The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.

L5 ANSWER 11 OF 45 USPATFULL on STN
AN 2003:311814 USPATFULL
TI Methods of making pharmaceutical compositions with minicells
IN Sabbadini, Roger A., Lakeside, CA, UNITED STATES
Klepper, Robert, San Diego, CA, UNITED STATES

PI US 2003219408 A1 20031127
AI US 2002-157320 A1 20020528 (10)
RLI Division of Ser. No. US 2002-154951, filed on 24 May 2002, PENDING
PRAI US 2002-359843P 20020225 (60)
US 2001-293566P 20010524 (60)
DT Utility
FS APPLICATION
LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR, IRVINE, CA, 92614
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 18632
AB The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.

L5 ANSWER 12 OF 45 USPATFULL on STN
AN 2003:300375 USPATFULL
TI Minicell-based delivery agents
IN Sabbadini, Roger A., Lakeside, CA, UNITED STATES
Klepper, Robert, San Diego, CA, UNITED STATES
Surber, Mark W., Coronado, CA, UNITED STATES
PI US 2003211599 A1 20031113
AI US 2002-157106 A1 20020528 (10)
RLI Division of Ser. No. US 2002-154951, filed on 24 May 2002, PENDING
PRAI US 2002-359843P 20020225 (60)
US 2001-293566P 20010524 (60)
DT Utility
FS APPLICATION
LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR, IRVINE, CA, 92614
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 18671
AB The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.

L5 ANSWER 13 OF 45 USPATFULL on STN
AN 2003:299865 USPATFULL
TI Minicell-based selective absorption
IN Berkley, Neil, San Diego, CA, UNITED STATES
Sabbadini, Roger A., Lakeside, CA, UNITED STATES
PI US 2003211086 A1 20031113
AI US 2002-157073 A1 20020528 (10)
PRAI US 2001-295566P 20010605 (60)
US 2002-359843P 20020225 (60)
DT Utility
FS APPLICATION
LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR, IRVINE, CA, 92614
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 18553
AB The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.

L5 ANSWER 14 OF 45 USPATFULL on STN
AN 2003:294815 USPATFULL
TI Pharmaceutical compositions with minicells

IN Berkley, Neil, San Diego, CA, UNITED STATES
Klepper, Robert, San Diego, CA, UNITED STATES
Sabbadini, Roger A., Lakeside, CA, UNITED STATES
PI US 2003207833 A1 20031106
AI US 2002-156811 A1 20020528 (10)
PRAI US 2002-359843P 20020225 (60)
DT Utility
FS APPLICATION
LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR, IRVINE, CA, 92614
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 18585
AB The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.

L5 ANSWER 15 OF 45 USPATFULL on STN
AN 2003:288723 USPATFULL
TI Conjugated minicells
IN Surber, Mark W., Coronado, CA, UNITED STATES
Klepper, Robert, San Diego, CA, UNITED STATES
PI US 2003203481 A1 20031030
AI US 2002-157213 A1 20020528 (10)
PRAI US 2002-359843P 20020225 (60)
DT Utility
FS APPLICATION
LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR, IRVINE, CA, 92614
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 18551
AB The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.

L5 ANSWER 16 OF 45 USPATFULL on STN
AN 2003:288653 USPATFULL
TI Methods of minicell-based delivery
IN Sabbadini, Roger A., Lakeside, CA, UNITED STATES
Berkley, Neil, San Diego, CA, UNITED STATES
Klepper, Robert, San Diego, CA, UNITED STATES
Surber, Mark W., Coronado, CA, UNITED STATES
PI US 2003203411 A1 20031030
AI US 2002-156792 A1 20020528 (10)
PRAI US 2001-295566P 20010605 (60)
US 2002-359843P 20020225 (60)
DT Utility
FS APPLICATION
LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR, IRVINE, CA, 92614
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 18582
AB The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.

L5 ANSWER 17 OF 45 USPATFULL on STN
AN 2003:288179 USPATFULL
TI Minicell-based diagnostics

IN Sabbadini, Roger A., Lakeside, CA, UNITED STATES
Klepper, Robert, San Diego, CA, UNITED STATES
Berkley, Neil, San Diego, CA, UNITED STATES
PI US 2003202937 A1 20031030
AI US 2002-157178 A1 20020528 (10)
PRAI US 2001-295566P 20010605 (60)
US 2002-359843P 20020225 (60)
DT Utility
FS APPLICATION
LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR, IRVINE, CA, 92614
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 18527
AB The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.

L5 ANSWER 18 OF 45 USPATFULL on STN
AN 2003:282746 USPATFULL
TI Membrane to membrane delivery
IN Surber, Mark W., Coronado, CA, UNITED STATES
Sabbadini, Roger A., Lakeside, CA, UNITED STATES
PI US 2003199089 A1 20031023
AI US 2002-157318 A1 20020528 (10)
PRAI US 2001-295566P 20010605 (60)
US 2002-359843P 20020225 (60)
DT Utility
FS APPLICATION
LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR, IRVINE, CA, 92614
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 18530
AB The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.

L5 ANSWER 19 OF 45 USPATFULL on STN
AN 2003:282745 USPATFULL
TI Minicell-based gene therapy
IN Sabbadini, Roger A., Lakeside, CA, UNITED STATES
Berkley, Neil, San Diego, CA, UNITED STATES
Surber, Mark W., Coronado, CA, UNITED STATES
PI US 2003199088 A1 20031023
AI US 2002-156902 A1 20020528 (10)
PRAI US 2001-295566P 20010605 (60)
US 2002-359843P 20020225 (60)
DT Utility
FS APPLICATION
LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR, IRVINE, CA, 92614
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 15300
AB The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.

L5 ANSWER 20 OF 45 USPATFULL on STN
AN 2003:282662 USPATFULL

TI Solid supports with minicells
IN Sabbadini, Roger, Lakeside, CA, UNITED STATES
Klepper, Robert, San Diego, CA, UNITED STATES
PI US 2003199005 A1 20031023
AI US 2002-157166 A1 20020528 (10)
RLI Division of Ser. No. US 2002-154951, filed on 24 May 2002, PENDING
PRAI US 2002-359843P 20020225 (60)
US 2001-293566P 20010524 (60)
DT Utility
FS APPLICATION
LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR, IRVINE, CA, 92614
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 18494
AB The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.

L5 ANSWER 21 OF 45 USPATFULL on STN
AN 2003:282653 USPATFULL
TI Minicell libraries
IN Surber, Mark W., Coronado, CA, UNITED STATES
Berkley, Neil, San Diego, CA, UNITED STATES
Gerhart, William, La Mesa, CA, UNITED STATES
Sabbadini, Roger A., Lakeside, CA, UNITED STATES
PI US 2003198996 A1 20031023
AI US 2002-157147 A1 20020528 (10)
RLI Division of Ser. No. US 2002-154951, filed on 24 May 2002, PENDING
PRAI US 2001-293566P 20010524 (60)
US 2002-359843P 20020225 (60)
DT Utility
FS APPLICATION
LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR, IRVINE, CA, 92614
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 18482
AB The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.

L5 ANSWER 22 OF 45 USPATFULL on STN
AN 2003:282652 USPATFULL
TI Forward screening with minicells
IN Sabbadini, Roger A., Lakeside, CA, UNITED STATES
Berkley, Neil, San Diego, CA, UNITED STATES
Surber, Mark W., Coronado, CA, UNITED STATES
Gerhart, William, La Mesa, CA, UNITED STATES
PI US 2003198995 A1 20031023
AI US 2002-156831 A1 20020528 (10)
RLI Division of Ser. No. US 2002-154951, filed on 24 May 2002, PENDING
PRAI US 2002-359843P 20020225 (60)
US 2001-293566P 20010524 (60)
DT Utility
FS APPLICATION
LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR, IRVINE, CA, 92614
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 18533
AB The invention provides compositions and methods for the production of

achromosomal and anucleate cells useful for applications such as diagnostic and therapeutic uses, as well as research tools and agents for drug discovery.

L5 ANSWER 23 OF 45 USPATFULL on STN
AN 2003:277157 USPATFULL
TI Diagnosis and management of infection caused by ***chlamydia***
IN Mitchell, William M., Nashville, TN, UNITED STATES
Stratton, Charles W., Nashville, TN, UNITED STATES
PI US 2003195184 A1 20031016
US 6756369 B2 20040629
AI US 2002-101279 A1 20020319 (10)
RLI Continuation of Ser. No. US 1998-73661, filed on 6 May 1998, GRANTED, Pat. No. US 6579854 Continuation-in-part of Ser. No. US 1998-25521, filed on 18 Feb 1998, ABANDONED Continuation-in-part of Ser. No. US 1997-911593, filed on 14 Aug 1997, ABANDONED Continuation-in-part of Ser. No. US 1998-73661, filed on 6 May 1998, GRANTED, Pat. No. US 6579854 Continuation-in-part of Ser. No. US 1998-25176, filed on 18 Feb 1998, GRANTED, Pat. No. US 6258532 Continuation-in-part of Ser. No. US 1997-911593, filed on 14 Aug 1997, ABANDONED
PRAI US 1997-45739P 19970506 (60)
US 1997-45779P 19970506 (60)
US 1997-45780P 19970506 (60)
US 1997-45784P 19970506 (60)
US 1997-45787P 19970506 (60)
US 1997-45689P 19970506 (60)
DT Utility
FS APPLICATION
LREP CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110
CLMN Number of Claims: 36
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 4849
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides a unique approach for the diagnosis and management of infections by ***Chlamydia*** species, particularly C. pneumoniae. The invention is based, in part, upon the discovery that a combination of agents directed toward the various stages of the ***chlamydial*** life cycle is effective in substantially reducing infection. Products comprising combination of antichlamydial agents, novel compositions and pharmaceutical packs are also described.

L5 ANSWER 24 OF 45 USPATFULL on STN
AN 2003:276773 USPATFULL
TI Minicell compositions and methods
IN Surber, Mark W., Coronado, CA, UNITED STATES
Sabbadini, Roger A., Lakeside, CA, UNITED STATES
PI US 2003194798 A1 20031016
AI US 2002-154951 A1 20020524 (10)
PRAI US 2001-293566P 20010524 (60)
US 2002-359843P 20020225 (60)
DT Utility
FS APPLICATION
LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR, IRVINE, CA, 92614
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 18583
AB The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.

L5 ANSWER 25 OF 45 USPATFULL on STN
AN 2003:276689 USPATFULL
TI Minicell-based transformation

IN Sabbadini, Roger A., Lakeside, CA, UNITED STATES
Berkley, Neil, San Diego, CA, UNITED STATES
Surber, Mark W., Coronado, CA, UNITED STATES
PI US 2003194714 A1 20031016
AI US 2002-157299 A1 20020528 (10)
PRAI US 2001-295566P 20010605 (60)
US 2002-359843P 20020225 (60)
DT Utility
FS APPLICATION
LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR, IRVINE, CA, 92614
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 18595
AB The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.

L5 ANSWER 26 OF 45 USPATFULL on STN
AN 2003:271146 USPATFULL
TI Minicell-producing parent cells
IN Surber, Mark W., Coronado, CA, UNITED STATES
Sabbadini, Roger A., Lakeside, CA, UNITED STATES
Segall, Anca M., San Diego, CA, UNITED STATES
Berkley, Neil, San Diego, CA, UNITED STATES
PI US 2003190749 A1 20031009
AI US 2002-157215 A1 20020528 (10)
RLI Division of Ser. No. US 2002-154951, filed on 24 May 2002, PENDING
PRAI US 2002-359843P 20020225 (60)
US 2001-293566P 20010524 (60)
DT Utility
FS APPLICATION
LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR, IRVINE, CA, 92614
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 18577
AB The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.

L5 ANSWER 27 OF 45 USPATFULL on STN
AN 2003:271080 USPATFULL
TI Minicell-based rational drug design
IN Sabbadini, Roger A., Lakeside, CA, UNITED STATES
Surber, Mark W., Coronado, CA, UNITED STATES
PI US 2003190683 A1 20031009
AI US 2002-157302 A1 20020528 (10)
RLI Division of Ser. No. US 2002-154951, filed on 24 May 2002, PENDING
PRAI US 2002-359843P 20020225 (60)
US 2001-293566P 20010524 (60)
DT Utility
FS APPLICATION
LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR, IRVINE, CA, 92614
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 18539
AB The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.

L5 ANSWER 28 OF 45 USPATFULL on STN
AN 2003:270998 USPATFULL
TI Target display on minicells
IN Sabbadini, Roger A., Lakeside, CA, UNITED STATES
Berkley, Neil, San Diego, CA, UNITED STATES
Surber, Mark W., Coronada, CA, UNITED STATES
PI US 2003190601 A1 20031009
AI US 2002-157096 A1 20020528 (10)
RLI Division of Ser. No. US 2002-154951, filed on 24 May 2002, PENDING
PRAI US 2002-359843P 20020225 (60)
US 2001-293566P 20010524 (60)
DT Utility
FS APPLICATION
LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR, IRVINE, CA, 92614
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 18581
AB The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.

L5 ANSWER 29 OF 45 USPATFULL on STN
AN 2003:244934 USPATFULL
TI Diagnosis and management of infection caused by ***Chlamydia***
IN Mitchell, William M., Nashville, TN, UNITED STATES
Stratton, Charles W., Nashville, TN, UNITED STATES
PI US 2003171348 A1 20030911
US 6664239 B2 20031216
AI US 2002-100785 A1 20020319 (10)
RLI Continuation of Ser. No. US 1998-73661, filed on 6 May 1998, PENDING Continuation-in-part of Ser. No. US 1998-25521, filed on 18 Feb 1998, ABANDONED Continuation-in-part of Ser. No. US 1997-911593, filed on 14 Aug 1997, ABANDONED
PRAI US 1997-45739P 19970506 (60)
US 1997-45779P 19970506 (60)
US 1997-45780P 19970506 (60)
US 1997-45784P 19970506 (60)
US 1997-45787P 19970506 (60)
US 1997-45689P 19970506 (60)
DT Utility
FS APPLICATION
LREP CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110
CLMN Number of Claims: 43
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 4871
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides a unique approach for the diagnosis and management of infections by ***Chlamydia*** species, particularly C. pneumoniae. The invention is based, in part, upon the discovery that a combination of agents directed toward the various stages of the ***chlamydial*** life cycle is effective in substantially reducing infection. Products comprising combination of antichlamydial agents, novel compositions and pharmaceutical packs are also described.

L5 ANSWER 30 OF 45 USPATFULL on STN
AN 2003:238122 USPATFULL
TI Minicell-based transfection
IN Sabbadini, Roger A., Lakeside, CA, UNITED STATES
Berkley, Neil, San Diego, CA, UNITED STATES
PI US 2003166279 A1 20030904
AI US 2002-157391 A1 20020528 (10)
RLI Division of Ser. No. US 2002-154951, filed on 24 May 2002, PENDING

PRAI US 2002-359843P 20020225 (60)
US 2001-293566P 20010524 (60)
DT Utility
FS APPLICATION
LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR, IRVINE, CA, 92614
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 18548
AB The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.

L5 ANSWER 31 OF 45 USPATFULL on STN
AN 2003:237942 USPATFULL
TI Minicells comprising membrane proteins
IN Sabbadini, Roger A., Lakeside, CA, UNITED STATES
Surber, Mark W., Coronado, CA, UNITED STATES
Berkley, Neil, San Diego, CA, UNITED STATES
Segall, Anca M., San Diego, CA, UNITED STATES
Klepper, Robert, San Diego, CA, UNITED STATES
PI US 2003166099 A1 20030904
AI US 2002-157305 A1 20020528 (10)
PRAI US 2001-295566P 20010605 (60)
US 2002-359843P 20020225 (60)
DT Utility
FS APPLICATION
LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR, IRVINE, CA, 92614
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 18580
AB The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.

L5 ANSWER 32 OF 45 USPATFULL on STN
AN 2003:231611 USPATFULL
TI Compositions and methods for the transport of biologically active agents across cellular barriers
IN Houston, L. L., Del Mar, CA, UNITED STATES
Sheridan, Philip J., San Diego, CA, UNITED STATES
Hawley, Stephen B., San Diego, CA, UNITED STATES
Glynn, Jacqueline M., San Diego, CA, UNITED STATES
Chapin, Steven, San Diego, CA, UNITED STATES
PI US 2003161809 A1 20030828
AI US 2001-969748 A1 20011002 (9)
PRAI US 2000-237929P 20001002 (60)
US 2000-248478P 20001113 (60)
US 2000-248819P 20001114 (60)
US 2001-267601P 20010209 (60)
DT Utility
FS APPLICATION
LREP FOLEY & LARDNER, P.O. BOX 80278, SAN DIEGO, CA, 92138-0278
CLMN Number of Claims: 53
ECL Exemplary Claim: 1
DRWN 32 Drawing Page(s)
LN.CNT 11304
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed herein are complexes and compounds that pass through cellular barriers to deliver compounds into, through and out of cells, and methods of producing and using such complexes and compounds. The complexes and compounds of the invention comprise a biologically active

portion and a targeting element directed to a ligand that confers transcellular, transcytotic or paracellular transporting properties to an agent specifically bound to the ligand, with the proviso that the targeting element is not an antibody. Also disclosed are complexes and compounds that comprise two or more targeting elements directed to a ligand that confers transcellular, transcytotic or paracellular transporting properties to an agent specifically bound to the ligand. Preferred ligands include but are not limited to the stalk of pIgR, a pIgR domain, an amino acid sequence that is conserved among pIgR's from different animals, and one of several regions of pIgR defined herein.

L5 ANSWER 33 OF 45 USPATFULL on STN
AN 2003:213265 USPATFULL
TI Method of stimulating and immune response by administration of host organisms that express intimin alone of as a fusion protein with one of more other antigens
IN Stewart, C. Neal, JR., Greensboro, NC, UNITED STATES
McKee, Marian L., Great Falls, VA, UNITED STATES
O'Brien, Alison D., Bethesda, MD, UNITED STATES
Wachtel, Marian R., Albany, CA, UNITED STATES
PA Henry M. Jackson Foundation for the Advancement of Military Medicine (U.S. corporation)
PI US 2003147902 A1 20030807
AI US 2002-150058 A1 20020520 (10)
RLI Division of Ser. No. US 2000-696188, filed on 26 Oct 2000, GRANTED, Pat. No. US 6406885 Division of Ser. No. US 1997-840466, filed on 18 Apr 1997, GRANTED, Pat. No. US 6261561
PRAI US 1996-15938P 19960422 (60)
US 1996-15657P 19960419 (60)
DT Utility
FS APPLICATION
LREP FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LLP, 1300 I STREET, NW, WASHINGTON, DC, 20005
CLMN Number of Claims: 36
ECL Exemplary Claim: 1
DRWN 23 Drawing Page(s)
LN.CNT 3124
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention satisfies needs in the art by providing intimin, the Enterohemorrhagic Escherichia coli (EHEC) adherence protein, alone or as a fusion protein with one or more other antigens, expressed by transgenic plants and the use of those plants as vehicles for stimulating a protective immune response against EHEC and the one or more other antigens. Various plant species are transformed to protect various animal species and also humans against EHEC, against pathogens expressing intimin-like proteins, and against pathogens expressing any of the one or more other antigens to which intimin may be fused.

The eae gene encoding intimin, a functional portion thereof, or a recombination that encodes a fusion protein is put under the control of a constitutive plant promoter in a plasmid and the plasmid is introduced into plants by the type of transformation appropriate for the particular plant species. The engineered plants expressing intimin or the intimin fusion protein are then fed to animals and/or humans to elicit the production of antibodies, which protect the animals/humans against EHEC colonization and infection, and against pathogens expressing the one or more other antigens and any cross-reactive antigens. The invention may also be practiced by expressing the intimin or intimin fusion protein in other host organisms such as bacteria, yeast, and fungi.

L5 ANSWER 34 OF 45 USPATFULL on STN
AN 2003:105857 USPATFULL
TI Method to enhance an immune response of nucleic acid vaccination
IN Dalemans, Wilfried, Hoegaarden, BELGIUM
Mechelen, Marcelle Van, Wagnelee, BELGIUM
Bruck, Claudine, Rixensart, BELGIUM
Friede, Martin, Farnham, UNITED KINGDOM

PA SmithKline Beecham Biologicals, s.a. (non-U.S. corporation)
PI US 2003072768 A1 20030417
AI US 2002-292136 A1 20021112 (10)
RLI Continuation of Ser. No. US 2000-581368, filed on 12 Jun 2000, GRANTED, Pat. No. US 6500432 A 371 of International Ser. No. WO 1998-EP8152, filed on 11 Dec 1998, UNKNOWN
PRAI GB 1997-26555 19971216
DT Utility
FS APPLICATION
LREP GLAXOSMITHKLINE, Corporate Intellectual Property - UW2220, P.O. Box 1539, King of Prussia, PA, 19406-0939
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 1004
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides a method to enhance an immune response of nucleic acid vaccination by simultaneous administration of a polynucleotide and a polypeptide of interest.

L5 ANSWER 35 OF 45 USPATFULL on STN
AN 2003:161945 USPATFULL
TI Diagnosis and management of infection caused by ***chlamydia***
IN Mitchell, William M., Nashville, TN, United States
Stratton, Charles W., Nashville, TN, United States
PA Vanderbilt University, Nashville, TN, United States (U.S. corporation)
PI US 6579854 B1 20030617
AI US 1998-73661 19980506 (9)
RLI Continuation-in-part of Ser. No. US 1998-25174, filed on 18 Feb 1998 Continuation-in-part of Ser. No. US 1998-25521, filed on 18 Feb 1998, now abandoned Continuation-in-part of Ser. No. US 1998-25176, filed on 18 Feb 1998, now patented, Pat. No. US 6258532 Continuation-in-part of Ser. No. US 1997-911593, filed on 14 Aug 1997, now abandoned
PRAI US 1997-45689P 19970506 (60)
US 1997-45739P 19970506 (60)
US 1997-45779P 19970506 (60)
US 1997-45780P 19970506 (60)
US 1997-45787P 19970506 (60)
US 1996-23921P 19960814 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Weddington, Kevin E.
LREP Clark & Elbing LLP
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN 6 Drawing Figure(s); 4 Drawing Page(s)
LN.CNT 4353
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides a unique approach for the diagnosis and management of infections by ***Chlamydia*** species, particularly C. pneumoniae. The invention is based, in part, upon the discovery that a combination of agents directed toward the various stages of the ***chlamydial*** life cycle is effective in substantially reducing infection. Products comprising combination of antichlamydial agents, novel compositions and pharmaceutical packs are also described.

L5 ANSWER 36 OF 45 USPATFULL on STN
AN 2002:205855 USPATFULL
TI DNA IMMUNIZATION AGAINST ***CHLAMYDIA*** INFECTION
IN BRUNHAM, ROBERT C., WINNIPEG, CANADA
PI US 2002110542 A1 20020815
US 6696421 B2 20040224
AI US 1999-214606 A1 19990812 (9)
WO 1997-CA500 19970711
DT Utility
FS APPLICATION
LREP SIM & MCBURNEY, 330 UNIVERSITY AVENUE, 6TH FLOOR, TORONTO, M5G1R7

CLMN Number of Claims: 33
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 878
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Nucleic acid, including DNA, immunization to generate a protective immune response in a host, including humans, to a major outer membrane protein of a strain of ***Chlamydia*** , preferably contains a nucleotide sequence encoding a MOMP or a MOMP fragment that generates antibodies that specifically react with MOMP and a promoter sequence operatively coupled to the first nucleotide sequence for expression of the MOMP in the host. The ***nonreplicating*** ***vector*** may be formulated with a pharmaceutically acceptable carrier for in vivo administration to the host.

L5 ANSWER 37 OF 45 USPATFULL on STN
AN 2002:12031 USPATFULL
TI HISTIDINE-TAGGED INTIMIN AND METHODS OF USING INTIMIN TO STIMULATE AN IMMUNE RESPONSE AND AS AN ANTIGEN CARRIER WITH TARGETING CAPABILITY
IN MCKEE, MARIAN L., GREAT FALLS, VA, UNITED STATES
O'BRIEN, ALISON D., BETHESDA, MD, UNITED STATES
WACHTEL, MARIAN R., GAITHERSBURG, MD, UNITED STATES
PA Henry M. Jackson Foundation for the Advancement of Military Medicine (U.S. corporation)
PI US 2002006407 A1 20020117
AI US 1997-837459 A1 19970418 (8)
PRAI US 1996-15657P 19960419 (60)
US 1996-15936P 19960422 (60)
DT Utility
FS APPLICATION
LREP FINNEGAN HENDERSON FARABOW GARRETT &, DUNNER, 1300 I STREET NW, WASHINGTON, DC, 200053315
CLMN Number of Claims: 50
ECL Exemplary Claim: 1
DRWN 18 Drawing Page(s)
LN.CNT 2287
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention describes the isolation and purification of histidine-tagged functional portions of intimin (his-tagged intimin or his-intimin), a protein associated with the ability of certain strains of pathogenic bacteria to adhere to epithelial cells. The invention further describes the use of intimin as an antigen to promote a protective immune response. In addition, the invention describes the combination of intimin with one or more other antigens and administration of the combination to promote a protective immune response against intimin and the one or more antigens.

One aspect of the invention is the administration of intimin to target specific epithelial cells to promote a protective immune response to intimin proteins. Additional aspects of the invention include the use of intimin or intimin combined with one or more antigens and administration of the combination to target gastrointestinal mucosa and stimulate an immune response. Additionally, the invention describes administration of the combination of intimin combined with drugs, to provide a means for targeted delivery of drugs to specific epithelial cells. Other aspects of the invention include the production of antibodies directed against his-intimin and methods of using such antibodies to provide passive immune protection, and in an assay system.

L5 ANSWER 38 OF 45 USPATFULL on STN
AN 2002:346653 USPATFULL
TI Method to enhance an immune response of nucleic acid vaccination
IN Dalemans, Wilfried, Hoegaarden, BELGIUM
Van Mechelen, Marcelle, Wagnelee, BELGIUM
Bruck, Claudine, Rixensart, BELGIUM
Friede, Martin, Farnham, UNITED KINGDOM
PA SmithKline Beecham Biologicals, S.A., Rixensart, BELGIUM (non-U.S.

corporation)
PI US 6500432 B1 20021231
WO 9930733 19990624
AI US 2000-581368 20000612 (9)
WO 1998-EP8152 19981211
PRAI GB 1997-26555 19971216
DT Utility
FS GRANTED
EXNAM Primary Examiner: Priebe, Scott D.
LREP Marjarian, William R., Venetianer, Stephen, Kinzig, Charlie M.
CLMN Number of Claims: 2
ECL Exemplary Claim: 1
DRWN 6 Drawing Figure(s); 6 Drawing Page(s)
LN.CNT 941
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides a method to enhance an immune response of nucleic acid vaccination by simultaneous administration of a polynucleotide and a polypeptide of interest.

L5 ANSWER 39 OF 45 USPATFULL on STN
AN 2002:144099 USPATFULL
TI Plants and plant cells expressing histidine tagged intimin
IN Stewart, Jr., C. Neal, Greensboro, NC, United States
McKee, Marian L., Great Falls, VA, United States
O'Brien, Alison D., Bethesda, MD, United States
Wachtel, Marian R., Gaithersburg, MD, United States
PA Henry M. Jackson Foundation for the Advancement of Military Medicine, Rockville, MD, United States (U.S. corporation)
PI US 6406885 B1 20020618
AI US 2000-696188 20001026 (9)
RLI Division of Ser. No. US 1997-840466, filed on 18 Apr 1997, now patented, Pat. No. US 6261561
PRAI US 1996-15938P 19960422 (60)
US 1996-15657P 19960419 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Navarro, Mark; Assistant Examiner: Portner, Ginny Allen
LREP Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 23 Drawing Figure(s); 23 Drawing Page(s)
LN.CNT 2819
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention satisfies needs in the art by providing intimin, the Enterohemorrhagic Escherichia coli (EHEC) adherence protein, alone or as a fusion protein with one or more other antigens, expressed by transgenic plants and the use of those plants as vehicles for stimulating a protective immune response against EHEC and the one or more other antigens. Various plant species are transformed to protect various animal species and also humans against EHEC, against pathogens expressing intimin-like proteins, and against pathogens expressing any of the one or more other antigens to which intimin may be fused.

The eae gene encoding intimin, a functional portion thereof, or a recombination that encodes a fusion protein is put under the control of a constitutive plant promoter in a plasmid and the plasmid is introduced into plants by the type of transformation appropriate for the particular plant species. The engineered plants expressing intimin or the intimin fusion protein are then fed to animals and/or humans to elicit the production of antibodies, which protect the animals/humans against EHEC colonization and infection, and against pathogens expressing the one or more other antigens and any cross-reactive antigens. The invention may also be practiced by expressing the intimin or intimin fusion protein in other host organisms such as bacteria, yeast, and fungi.

L5 ANSWER 40 OF 45 USPATFULL on STN

AN 2002:69812 USPATFULL
TI Parapoxviruses containing foreign DNA, their production and their use in vaccines
IN Schmeer, Norbert, Haan, GERMANY, FEDERAL REPUBLIC OF
Strube, Walter, Pulheim, GERMANY, FEDERAL REPUBLIC OF
Buttner, Mathias, Tubingen, GERMANY, FEDERAL REPUBLIC OF
Rziha, Hans-Joachim, Koln, GERMANY, FEDERAL REPUBLIC OF
PA Bayer Aktiengesellschaft, Leverkusen, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)
PI US 6365393 B1 20020402
WO 9732029 19970904
AI US 1998-125642 19980820 (9)
WO 1997-EP729 19970217
19980820 PCT 371 date
PRAI DE 1996-19607458 19960228
DE 1996-19639601 19960926
DT Utility
FS GRANTED
EXNAM Primary Examiner: Mosher, Mary E.
LREP Gil, Joseph C., Akorli, Godfried R.
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN 8 Drawing Figure(s); 8 Drawing Page(s)
LN.CNT 2380
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to recombinantly prepared parapoxviruses which carry, in their genomes, deletions or insertions in the form of foreign hereditary information and contain hereditary information, to the preparation of such constructs and to their use in vaccines.

L5 ANSWER 41 OF 45 USPATFULL on STN
AN 2001:170746 USPATFULL
TI Methods of preparing and using a viral ***vector*** library
IN Kovesdi, Imre, Rockville, MD, United States
McVey, Duncan L., Derwood, MD, United States
Wickham, Thomas J., Germantown, MD, United States
Bruder, Joseph T., Ijamsville, MD, United States
Brough, Douglas E., Olney, MD, United States
PA GenVec, Inc., Gaithersburg, MD, United States (U.S. corporation)
PI US 2001026794 A1 20011004
AI US 2001-780526 A1 20010209 (9)
PRAI US 2000-181321P 20000209 (60)
US 2000-205269P 20000518 (60)
US 2000-209158P 20000602 (60)
DT Utility
FS APPLICATION
LREP LEYDIG VOIT & MAYER, LTD, TWO PRUDENTIAL PLAZA, SUITE 4900, 180 NORTH STETSON AVENUE, CHICAGO, IL, 60601-6780
CLMN Number of Claims: 53
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 2421
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides a library of viral ***vectors*** , wherein each member comprises a first heterologous DNA encoding a first gene product and a second heterologous DNA encoding a second gene product. The first heterologous DNA is common to each member of the library, while the second heterologous DNA varies between members of the library. The present invention additionally provides a method of constructing a library of viral ***vectors*** . The method comprises carrying out homologous recombination between a first DNA molecule and a second DNA molecule to form a pool of intermediate viral ***vector*** genomes. One or more linear third DNA molecules are ligated into the pool of intermediate viral genomes to produce a library of viral ***vector*** genomes. Alternatively, homologous recombination between linear DNA molecules and recipient DNA molecules produces a library of viral ***vector*** genomes. The library of viral ***vector***

genomes is converted into a library of viral ***vectors*** .

L5 ANSWER 42 OF 45 USPATFULL on STN
AN 2001:191262 USPATFULL
TI DNA construct for immunization or gene therapy
IN Ricigliano, Joseph W., 1880 Laurelhurst Dr., Salt Lake City, UT, United States 84108
Araneo, Barbara A., 2434 Kentucky Ave., Salt Lake City, UT, United States 84117
PI US 6310196 B1 20011030
AI US 1998-119264 19980720 (9)
RLI Continuation of Ser. No. US 1995-530529, filed on 19 Sep 1995, now patented, Pat. No. US 5795872
DT Utility
FS GRANTED
EXNAM Primary Examiner: Yucel, Remy
CLMN Number of Claims: 3
ECL Exemplary Claim: 1
DRWN 7 Drawing Figure(s); 7 Drawing Page(s)
LN.CNT 660
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to a DNA construct which is useful for immunization or gene therapy. The construct of the invention comprises muscle specific regulatory elements, such as a promoter or a promoter and one or more enhancer elements, and a DNA sequence under control of the muscle specific regulatory elements. Several DNA sequences may be incorporated into the DNA construct. In one embodiment, the DNA sequence codes for an antigen, antigenic determinant or an epitope of an antigen. In a second embodiment, the DNA sequence is a normal muscle gene which is effected in a muscle disease. In a third embodiment, the DNA sequence is an antisense for blocking an abnormal muscle gene. In a fourth embodiment, the DNA sequence codes for a protein which circulates in the mammalian blood or lymphatic systems. The present invention is useful for ameliorating the effects of diseases of muscle by expression of the normal gene or blocking abnormal gene expression within muscle cells, for the heterologous expression of a transgene which codes for a circulating protein or a protein which modifies a disease state in which muscle is not primarily involved and for vaccine development.

L5 ANSWER 43 OF 45 USPATFULL on STN
AN 2001:111832 USPATFULL
TI Method of stimulating an immune response by administration of host organisms that express intimin alone or as a fusion protein with one or more other antigens
IN Stewart, Jr., C. Neal, Greensboro, NC, United States
McKee, Marian L., Great Falls, VA, United States
O'Brien, Alison D., Bethesda, MD, United States
Wachtel, Marian R., Albany, CA, United States
PA Henry M. Jackson Foundation for the Advancement of Military Medicine, Rockville, MD, United States (U.S. corporation)
PI US 6261561 B1 20010717
AI US 1997-840466 19970418 (8)
PRAI US 1996-15657P 19960419 (60)
US 1996-15938P 19960422 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Smith, Lynette R F.; Assistant Examiner: Portner, Ginny Allen
LREP Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 23 Drawing Figure(s); 23 Drawing Page(s)
LN.CNT 2817
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention satisfies needs in the art by providing intimin, the Enterohemorrhagic Escherichia coli (EHEC) adherence protein, alone or as a fusion protein with one or more other antigens, expressed by

transgenic plants and the use of those plants as vehicles for stimulating a protective immune response against EHEC and the one or more other antigens. Various plant species are transformed to protect various animal species and also humans against EHEC, against pathogens expressing intimin-like proteins, and against pathogens expressing any of the one or more other antigens to which intimin may be fused.

The eae gene encoding intimin, a functional portion thereof, or a recombination that encodes a fusion protein is put under the control of a constitutive plant promoter in a plasmid and the plasmid is introduced into plants by the type of transformation appropriate for the particular plant species. The engineered plants expressing intimin or the intimin fusion protein are then fed to animals and/or humans to elicit the production of antibodies, which protect the animals/humans against EHEC colonization and infection, and against pathogens expressing the one or more other antigens and any cross-reactive antigens. The invention may also be practiced by expressing the intimin or intimin fusion protein in other host organisms such as bacteria, yeast, and fungi.

L5 ANSWER 44 OF 45 USPATFULL on STN
AN 1998:98896 USPATFULL
TI DNA construct for immunization
IN Ricigliano, Joseph W., Salt Lake City, UT, United States
Araneo, Barbara A., Salt Lake City, UT, United States
PA Pharmadigm, Inc., Salt Lake City, UT, United States (U.S. corporation)
PI US 5795872 19980818
AI US 1995-530529 19950919 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Railey, Johnny
LREP Rothwell, Figg, Ernst & Kurz, P.C.
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN 7 Drawing Figure(s); 7 Drawing Page(s)
LN.CNT 787
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to a DNA construct which is useful for immunization or gene therapy. The construct of the invention comprises muscle specific regulatory elements, such as a promoter or a promoter and one or more enhancer elements, and a DNA sequence under control of the muscle specific regulatory elements. Several DNA sequences may be incorporated into the DNA construct. In one embodiment, the DNA sequence codes for an antigen, antigenic determinant or an epitope of an antigen. In a second embodiment, the DNA sequence is a normal muscle gene which is effected in a muscle disease. In a third embodiment, the DNA sequence is an antisense for blocking an abnormal muscle gene. In a fourth embodiment, the DNA sequence codes for a protein which circulates in the mammalian blood or lymphatic systems. The present invention is useful for ameliorating the effects of diseases of muscle by expression of the normal gene or blocking abnormal gene expression within muscle cells, for the heterologous expression of a transgene which codes for a circulating protein or a protein which modifies a disease state in which muscle is not primarily involved and for vaccine development.

L5 ANSWER 45 OF 45 USPATFULL on STN
AN 1998:9367 USPATFULL
TI Adenoviral-mediated cell targeting commanded by the adenovirus penton base protein
IN Wickham, Thomas J., Potomac, MD, United States
Kovesdi, Imre, Rockville, MD, United States
Roelvink, Petrus W., Gaithersburg, MD, United States
Brough, Douglas E., Otney, MD, United States
McVey, Duncan L., Derwood, MD, United States
Bruder, Joseph T., Frederick, MD, United States
PA GenVec, Inc., Rockville, MD, United States (U.S. corporation)
PI US 5712136 19980127
AI US 1996-634060 19960417 (8)

RLI Continuation-in-part of Ser. No. US 1994-303162, filed on 8 Sep 1994, now patented, Pat. No. US 5559099
DT Utility
FS Granted
EXNAM Primary Examiner: Elliott, George G.; Assistant Examiner: Schwartzman, Robert
LREP Leydig, Voit & Mayer, Ltd.
CLMN Number of Claims: 52
ECL Exemplary Claim: 1
DRWN 24 Drawing Figure(s); 18 Drawing Page(s)
LN.CNT 3142
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method of introducing an adenovirus into a cell that comprises a particular cell surface binding site, as well as a chimeric adenovirus penton base protein and recombinant adenoviral ***vector*** comprising the chimeric adenovirus penton base protein for use in the method, are provided.